Safety and antigenicity of a purified preparation of Salmonella typhosa Vi antigen was evaluated in human volunteers. Dosages of Vi antigen at 25, 50, and 100 ,ug were less toxic than U.S. standard typhoid vaccine (lot 6A) containing 5 x 108 bacteria per dosage. Vi antigen in comparison with the standard typhoid vaccine induced higher hemagglutinating antibody but lower bactericidal antibody responses.
Typhoid fever remains a serious clinical and public health problem in many parts of the world. Although both field trials and volunteer studies have shown that inactivated cellular vaccines offer some protection (2, 7), adverse reactions to these vaccines are quite pronounced. Many attempts have been made to improve the efficacy and safety of typhoid vaccine in recent years (8) .
In their study of different types of typhoid vaccine, Wong et al. (16) isolated a Vi antigen from Salmonella typhosa by a mild precipitation method and studied its immunological properties in animals and tissue cultures. In animal studies, this Vi antigen was significantly more potent than Vi preparations from Citrobacter 5396/38, which had been used in the past for human study but was less toxic than cellular typhoid vaccines.
With respect to human protection, however, the importance of Vi antigen remains an enigma (16) . With a Vi antigen prepared from the causative bacterium, we are attempting to define the role of Vi antigen in human typhoid immunity. In this report results are presented on the safety and antigenicity of this antigen in human volunteers.
MATERIALS AND METHODS Vaccines. The U.S. standard typhoid vaccine (lot 6A), an acetone-inactivated and dried vaccine prepared from S. typhosa strain Ty 2 (3, 17), was used as a control vaccine.
Vi antigen (Vi-Ty 2) was isolated as described previously from S. typhosa strain Ty 2 (16).
Vaccination. U.S. standard typhoid vaccine (lot 6A) containing 5 x 108 bacteria in 0.5 ml or Vi antigen in dosages from 25 to 100 ,ug in 0. Landy and Lamb (11) with the following modifications: (i) fresh sheep erythrocytes were used; (ii) sensitized cells were suspended in saline at 0.5%. Vi-W, (16) Although the frequency of side effects with the Vi antigens was not less than that with the cellular vaccine 6A, the severity of both local and systemic reactions caused by the Vi anti- A booster injection with either vaccine preparation produced a mildly sore arm at the inoculation site; systemic symptoms and fever were rare. Reactivity from the booster was generally less noticeable than from the primary injection.
Vaccine immunogenicity. Hemagglutinating Vi antibody responses to immunization with vaccine 6A or the Vi antigen are summarized in Table 2 . All but two volunteers responded to either vaccine 6A or the Vi antigen with a rise in Vi antibody titer. The two nonresponders had pre-immunization anti-Vi titers of four and 32, respectively, and their titers remained unchanged after immunization with vaccine 6A. Injection of 25 ,ug of the Vi antigen elicited a significantly greater antibody response than vaccine 6A as assayed at 2 and 3 weeks, and the injection of either 50 or 100 ,ug of the Vi antigen induced significantly greater antibody response than vaccine 6A 2 and 3 weeks after the initial injection. Generally, 50-and 100-,ug dosages of the Vi antigen induced higher antibody responses than the 25-Ag dosage at 2 and 3 weeks; however, the differences were not statistically significant. No significant rises in Vi-antibody titers were observed 3 weeks later, after booster injections with either vaccine 6A or the Vi antigen had been given.
Both Vi antigen and vaccine 6A induced bactericidal antibody in volunteers, but higher antibody responses were observed in volunteers given vaccine 6A ( (7) and in other animals (4) depends at least in part on the presence of Vi antigen. The mouse potency assay for typhoid vaccines, which correlates well with field trial results of the acetone-inactivated and the phenol-heatinactivated vaccines in man (14) , is highly dependent on the Vi antigen (9, 17) . Moreover, the superiority of acetone-inactivated vaccine is attributable to fixation by acetone of the Vi antigen to the bacteria (18) .
Using a Vi preparation isolated from Citrobacter by the method of Webster et al. (15) , some "suggestive" but statistically inconclusive Geometric mean of hemagglutination titers to Vi antigen and titer range found for groups. "Titers at 6 weeks after booster injection with original vaccine at 3 weeks.
Geometric mean titers at all doses of Vi antigen are significantly greater than 6A titers at 2, 3, and 6 weeks (Student's t test, P < 0.05).
d ND, Not done. 
